Lovera D, Arbo A
Department of Pediatrics, Instituto de Medicina Tropical, Mexico.
J Chemother. 2005 Jun;17(3):283-8. doi: 10.1179/joc.2005.17.3.283.
The clinical and microbiological efficacy, as well as the tolerability of the amoxicillin/sulbactam combination as empiric treatment for complicated community-acquired pneumonia (CCAP) were evaluated in children from 3 months to 15 years with CCAP who were randomized 1:1 to receive either amoxicillin/sulbactam or cefuroxime. Of 234 patients hospitalized with CCAP in the study period (June, 1999-April, 2002), 62 patients qualified for the study: 32 received amoxicillin/sulbactam and 30 cefuroxime. Two were excluded. Demographic and clinical data showed that both groups were comparable at entry. One etiologic agent was identified in 55% of the patients, with Streptococcus pneumoniae being the most frequent. After treatment, the days of fever, duration of intravenous treatment, and hospitalization stay were similar in both groups. Overall favorable clinical responses were comparable: 97% for amoxicillin/sulbactam vs 100% for the comparative therapy. There was good tolerance to both drugs. Amoxicillin/sulbactam produced a satisfactory therapeutic outcome similar to that of cefuroxime for treatment of CCAP, and may be an appropriate choice for the treatment of this serious pediatric infection.
对3个月至15岁患有复杂性社区获得性肺炎（CCAP）的儿童，评估了阿莫西林/舒巴坦联合用药作为CCAP经验性治疗的临床和微生物学疗效以及耐受性，这些儿童按1:1随机分组，分别接受阿莫西林/舒巴坦或头孢呋辛治疗。在研究期间（1999年6月至2002年4月）因CCAP住院的234例患者中，62例符合研究条件：32例接受阿莫西林/舒巴坦治疗，30例接受头孢呋辛治疗。2例被排除。人口统计学和临床数据显示两组在入组时具有可比性。55%的患者鉴定出一种病原体，其中肺炎链球菌最为常见。治疗后，两组的发热天数、静脉治疗持续时间和住院时间相似。总体良好临床反应相当：阿莫西林/舒巴坦组为97%，对照治疗组为100%。两种药物耐受性良好。阿莫西林/舒巴坦治疗CCAP产生了与头孢呋辛相似的满意治疗效果，可能是治疗这种严重儿科感染的合适选择。
